Imatinib
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
86 Active assets in the Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide City of Hope Medical Center | Phase 3 | BBB |
Fludarabine Fred Hutchinson Cancer Center | Phase 3 | BBB |
Nilotinib Novartis Pharmaceuticals | Phase 4 | BBB |
METHOTREXATE M.D. Anderson Cancer Center | Phase 3 | BBB |
Therapeutic Allogeneic Lymphocytes University of Chicago | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →